<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="800" width="600">
	<fontspec id="0" size="10" family="ODLHHC+MinionPro" color="#231f20"/>
	<fontspec id="1" size="10" family="ODLHID+MinionMath" color="#231f20"/>
	<fontspec id="2" size="12" family="ODLHAE+Minion-Black" color="#231f20"/>
	<fontspec id="3" size="10" family="ODLHAD+MinionPro-It" color="#231f20"/>
<text top="44" left="51" width="5" height="10" font="0">2</text>
<text top="44" left="368" width="181" height="10" font="0">International Journal of Medicinal Chemistry</text>
<text top="74" left="66" width="225" height="10" font="0">This undertaking has, however, proven challenging</text>
<text top="85" left="51" width="240" height="10" font="0">because there are 12 catalytically active human CA isoforms,</text>
<text top="96" left="51" width="240" height="10" font="0">which are structurally homologous and share high sequence</text>
<text top="108" left="51" width="240" height="10" font="0">identity <a href="">[26, 43</a>]. Additionally, most of the conserved residues</text>
<text top="119" left="51" width="240" height="10" font="0">are located within the active site <a href="">[26</a>]. At the core of the</text>
<text top="131" left="51" width="240" height="10" font="0">human CA active site, a zinc metal is tetrahedrally coordi-</text>
<text top="142" left="51" width="240" height="10" font="0">nated to three imidazole rings from His 94, 96, and 119 (using</text>
<text top="153" left="51" width="240" height="10" font="0">CA II numbering) <a href="">[44–46]. </a>This coordinated zinc metal</text>
<text top="165" left="51" width="240" height="10" font="0">is essential for the catalytic conversion of carbon dioxide</text>
<text top="176" left="51" width="240" height="10" font="0">into bicarbonate and a proton in the presence of water, the</text>
<text top="187" left="51" width="240" height="10" font="0">physiological reaction catalyzed by CAs <a href="">[25, 44]. </a>The catalytic</text>
<text top="199" left="51" width="78" height="10" font="0">site is located in an</text>
<text top="197" left="132" width="6" height="13" font="1">∼</text>
<text top="199" left="138" width="16" height="10" font="0">15 ˚</text>
<text top="199" left="149" width="142" height="10" font="0">A conical cavity and is surrounded</text>
<text top="210" left="51" width="240" height="10" font="0">by both hydrophobic and hydrophilic regions that provide</text>
<text top="222" left="51" width="240" height="10" font="0">accessibility to solvent, carbon dioxide, bicarbonate, and</text>
<text top="233" left="51" width="74" height="10" font="0">inhibitors <a href="">[26, 47]</a>.</text>
<text top="244" left="66" width="225" height="10" font="0">Recently, a “selective pocket” was proposed to extend</text>
<text top="256" left="51" width="91" height="10" font="0">between 10 and 20 ˚</text>
<text top="256" left="137" width="154" height="10" font="0">A away from the catalytic zinc that</text>
<text top="267" left="51" width="240" height="10" font="0">may serve to aid in the design of CA isoform selective</text>
<text top="278" left="51" width="240" height="10" font="0">inhibitors <a href="">[47]. </a>This pocket, containing several amino acids</text>
<text top="290" left="51" width="240" height="10" font="0">that differ among the CA isoforms, is currently the focus for</text>
<text top="301" left="51" width="240" height="10" font="0">designing isoform specific inhibitors, using the extended tail</text>
<text top="312" left="51" width="240" height="10" font="0">approach <a href="">[26]. </a>Other approaches have also been adopted in</text>
<text top="324" left="51" width="240" height="10" font="0">the development of isoform specific inhibitors that interact in</text>
<text top="335" left="51" width="240" height="10" font="0">the less conserved regions, outside of the active site, to inhibit</text>
<text top="347" left="51" width="240" height="10" font="0">catalysis <a href="">[25]. </a>CAs also exhibit a slower esterase activity</text>
<text top="358" left="51" width="240" height="10" font="0">mediated by the same catalytic pocket with a mechanism</text>
<text top="369" left="51" width="240" height="10" font="0">similar to that of the hydratase/CA activity <a href="">[48</a>]. Although the</text>
<text top="381" left="51" width="240" height="10" font="0">role of this second activity in cancer is currently unknown,</text>
<text top="392" left="51" width="240" height="10" font="0">many investigators often use the esterase reaction as an</text>
<text top="403" left="51" width="139" height="10" font="0">indicator of hydratase activity <a href="">[49].</a></text>
<text top="415" left="66" width="225" height="10" font="0">A variety of compounds and biologics have been</text>
<text top="426" left="51" width="240" height="10" font="0">described in the literature that target different CA isoforms in</text>
<text top="438" left="51" width="240" height="10" font="0">many disease models. The potency, specificity, and efficacy of</text>
<text top="449" left="51" width="240" height="10" font="0">these inhibitors have been tested using different techniques</text>
<text top="460" left="51" width="240" height="10" font="0">and approaches. In this review, we focus on some of the</text>
<text top="472" left="51" width="240" height="10" font="0">biophysical, biochemical, and cell based approaches currently</text>
<text top="483" left="51" width="240" height="10" font="0">studied to evaluate the potency of CA targeted inhibitors and</text>
<text top="494" left="51" width="240" height="10" font="0">to decipher the role of CAs in cancer. Some of the approaches</text>
<text top="506" left="51" width="240" height="10" font="0">discussed include those that investigate inhibition of the CA</text>
<text top="517" left="51" width="240" height="10" font="0">enzymatic activity like esterase activity assays and stop flow</text>
<text top="528" left="51" width="240" height="10" font="0">kinetics and biophysical methods such as thermal shift assays,</text>
<text top="540" left="51" width="240" height="10" font="0">surface plasmon resonance, mass inlet mass spectroscopy</text>
<text top="551" left="51" width="240" height="10" font="0">(MIMS), X-ray crystallography, Cryo-EM, neutron crystal-</text>
<text top="563" left="51" width="240" height="10" font="0">lography, and nuclear magnetic resonance (NMR) (Figure <a href="">1).</a></text>
<text top="574" left="51" width="240" height="10" font="0">Other approaches that will be discussed include large-scale</text>
<text top="585" left="51" width="240" height="10" font="0">gene and protein expression, measure metabolism, pH reg-</text>
<text top="597" left="51" width="240" height="10" font="0">ulation, cell growth, migration, and invasion (Figure <a href="">2).</a></text>
<text top="608" left="51" width="240" height="10" font="0">Together, these methods will hopefully reveal the role of CAs</text>
<text top="619" left="51" width="211" height="10" font="0">in tumorigenesis, cancer progression, and metastasis.</text>
<text top="644" left="51" width="233" height="11" font="2"><b>2. Enzymatic Assays and Biophysical Methods</b></text>
<text top="657" left="62" width="220" height="11" font="2"><b>That Evaluate the Potency of CA Inhibitors</b></text>
<text top="676" left="51" width="240" height="10" font="0">There are many techniques and strategies that have been</text>
<text top="688" left="51" width="240" height="10" font="0">described in the literature that evaluate CA activity for both</text>
<text top="699" left="51" width="240" height="10" font="0">purified versions of the enzyme and “intact” cells. These</text>
<text top="711" left="51" width="240" height="10" font="0">studies have been performed in the presence and/or absence</text>
<text top="722" left="51" width="240" height="10" font="0">of CA targeting inhibitors. Some of the techniques include</text>
<text top="733" left="51" width="240" height="10" font="0">measuring CA esterase activity on an ester substrate or the</text>
<text top="74" left="309" width="240" height="10" font="0">conversion of carbon dioxide into bicarbonate and a proton,</text>
<text top="85" left="309" width="240" height="10" font="0">which include stop flow kinetics and MIMS. Biophysical</text>
<text top="96" left="309" width="240" height="10" font="0">approaches such as differential scanning fluorimetry (DSF),</text>
<text top="108" left="309" width="240" height="10" font="0">differential scanning calorimetry (DSC), isothermal titration</text>
<text top="119" left="309" width="240" height="10" font="0">calorimetry (ITC), and surface plasmon resonance (SPR) also</text>
<text top="131" left="309" width="240" height="10" font="0">demonstrate binding of CA inhibitors to different isoforms.</text>
<text top="142" left="309" width="240" height="10" font="0">These techniques, however, do not indicate the regions of the</text>
<text top="153" left="309" width="240" height="10" font="0">proteins where inhibitors bind or their mode of inhibition</text>
<text top="165" left="309" width="40" height="10" font="0">(Figure <a href="">1).</a></text>
<text top="176" left="324" width="225" height="10" font="0">Structural biology techniques such as those discussed</text>
<text top="187" left="309" width="240" height="10" font="0">in this review, X-ray crystallography, Cryo-EM, neutron</text>
<text top="199" left="309" width="240" height="10" font="0">crystallography, and NMR, have been used to determine CA</text>
<text top="210" left="309" width="240" height="10" font="0">structures, most often in complex with inhibitors (Figure <a href="">1).</a></text>
<text top="222" left="309" width="240" height="10" font="0">These strategies have provided information related to the</text>
<text top="233" left="309" width="240" height="10" font="0">structure of several CA isoforms and the interactions with CA</text>
<text top="244" left="309" width="240" height="10" font="0">targeted inhibitors. Supuran and coauthors have developed</text>
<text top="256" left="309" width="240" height="10" font="0">several CA inhibitors, and their modes of binding have been</text>
<text top="267" left="309" width="240" height="10" font="0">determined using one or more of the abovementioned tech-</text>
<text top="278" left="309" width="240" height="10" font="0">niques. These inhibitors can be subdivided into five groups:</text>
<text top="290" left="309" width="240" height="10" font="0">(1) compounds that interact directly with the catalytic zinc</text>
<text top="301" left="309" width="240" height="10" font="0">(sulfonamides and their isosteres, dithiocarbamates and their</text>
<text top="312" left="309" width="240" height="10" font="0">isosteres, hydroxamates, etc.); (2) compounds that anchor to</text>
<text top="324" left="309" width="240" height="10" font="0">the zinc bound water/hydroxide ion (phenols, polyamines,</text>
<text top="335" left="309" width="240" height="10" font="0">sulfocoumarins, etc.); (3) compounds that occlude the CA</text>
<text top="347" left="309" width="240" height="10" font="0">active site entrance (coumarins and their isosteres); (4)</text>
<text top="358" left="309" width="240" height="10" font="0">compounds that bind out of the active site region (carboxylic</text>
<text top="369" left="309" width="240" height="10" font="0">acid derivatives); and (5) compounds with unknown binding</text>
<text top="381" left="309" width="227" height="10" font="0">mechanisms (secondary/tertiary sulfonamides, etc.) <a href="">[25].</a></text>
<text top="405" left="309" width="169" height="11" font="2"><b>3. Enzymatic Assays (Figure <a href="">1(a))</a></b></text>
<text top="426" left="309" width="108" height="10" font="3"><i>3.1. Esterase Activity Assay.</i></text>
<text top="426" left="422" width="127" height="10" font="0">The CA esterase activity, which</text>
<text top="438" left="309" width="240" height="10" font="0">is similar in mechanism to its hydratase activity, was first</text>
<text top="449" left="309" width="240" height="10" font="0">observed and measured in the mid-1900s <a href="">[48]</a>. In this study,</text>
<text top="460" left="309" width="240" height="10" font="0">the authors showed that the esterase activity of human</text>
<text top="472" left="309" width="240" height="10" font="0">isoforms is significantly lower than that observed for the</text>
<text top="483" left="309" width="240" height="10" font="0">hydratase activity <a href="">[48]</a>. However, like the CA hydratase</text>
<text top="495" left="309" width="240" height="10" font="0">activity, the CA targeted small molecule inhibitor, aceta-</text>
<text top="506" left="309" width="240" height="10" font="0">zolamide, also inhibits its esterase activity <a href="">[48]. </a>Since the</text>
<text top="517" left="309" width="240" height="10" font="0">discovery of this similarity in inhibition, numerous studies</text>
<text top="529" left="309" width="240" height="10" font="0">have relied on the measure of CA esterase activity as a</text>
<text top="540" left="309" width="240" height="10" font="0">surrogate for selecting CA inhibitors that block hydratase</text>
<text top="551" left="309" width="240" height="10" font="0">activity <a href="">[49, 50]. </a>In this regard, a commercially available,</text>
<text top="563" left="309" width="240" height="10" font="0">high-throughput colorimetric assay has been developed to</text>
<text top="574" left="309" width="240" height="10" font="0">determine CA activity in biological samples, serum, and</text>
<text top="585" left="309" width="240" height="10" font="0">purified CA (BioVision Incorporated). This assay utilizes</text>
<text top="597" left="309" width="240" height="10" font="0">the esterase activity of an active CA on an ester substrate,</text>
<text top="608" left="309" width="240" height="10" font="0">which releases a chromophore. The released product (4-</text>
<text top="620" left="309" width="240" height="10" font="0">nitrophenol) can be readily measured and quantified using</text>
<text top="631" left="309" width="240" height="10" font="0">a microplate reader (absorbance 405 nm). In the presence</text>
<text top="642" left="309" width="240" height="10" font="0">of a CA specific inhibitor, the enzyme’s decrease in activity</text>
<text top="654" left="309" width="240" height="10" font="0">directly correlates to the decrease in absorbance. Currently,</text>
<text top="665" left="309" width="240" height="10" font="0">most of the CA related work using this technique has focused</text>
<text top="676" left="309" width="240" height="10" font="0">on purified recombinant proteins assaying only one CA at</text>
<text top="688" left="309" width="240" height="10" font="0">a time. Perhaps this assay can be optimized to measure</text>
<text top="699" left="309" width="240" height="10" font="0">CA activity in either cancer cells or lysates from different</text>
<text top="711" left="309" width="240" height="10" font="0">samples (both tumor and normal) although this might prove</text>
<text top="722" left="309" width="240" height="10" font="0">challenging as biological samples are much more complex</text>
<text top="733" left="309" width="240" height="10" font="0">often with more than one CA present. Assigning the activity</text>
</page>
</pdf2xml>
